Azitra Corp - AZTR Net earnings per share for the last four quarters

The development of Azitra, Inc. (AZTR) depends on the outcomes of genetically modified bacteria tests, which necessitates strict budget control. Diversification of hubs for transporting dermatological products mitigates operational risks. Robots analyzing the skin microbiome enhance research efficiency. The YoY ttm change in net income per share from GURU.Markets is derived from this chart, where the 87.80 level captures the latest values.

AZTR: Azitra, Inc. Net earnings per share (EPS TTM) 11/23/2025 - 11/15/2026

azitrainc.com - analytical breakdowns and key metrics (AZTR)

- current quotes and average value forecast:

Stock Price Azitra|AZTR - Analyst Consensus Forecast

- issuer market value details:

Market Capitalization Azitra Corporation|AZTR - Total Company Value

- book value of equity indicators:

Equity per Share Azitra|AZTR - Book Capitalization|Market Capitalization to Book Value Ratio azitrainc.com|AZTR - Cumulative Company Assets

- debt and liquidity data:

- earnings and valuation multiples information:

AZTR - Net Income|Expected Net Income Azitra, Inc.|AZTR - P/E Multiple|Market Cap to Projected Earnings Azitra Corporation|AZTR - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Azitra Corp|AZTR - Operating profit EBITDA|Net earnings per share for the last 12 months Azitra|AZTR - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months azitrainc.com|AZTR - Earnings growth in current year|Earnings growth forecast for next year Azitra, Inc.

- sales and revenue indicators:

AZTR - Company Sales|Company Expected Revenue Azitra Corp|AZTR - Market Cap to Revenue|Price to Expected Revenue Ratio Azitra Corporation|AZTR - Sales Growth YoY (Last Twelve Months)

Fundamental valuation:Azitra Inc (AZTR)

Analyzing business resilience to market downturns requires verification of actual profits. Azitra, Inc. (AZTR) has no commercial sales, existing on external capital to develop dermatological drugs. This annual percentage growth chart of EPS TTM measures the dynamics of net income per share over 12 months, identifying operating margin expansion. For a clinical-stage biotech, this indicator often shows negative values. Blindly trusting such figures without considering financing carries the risk of a drawdown.

Competitor analysis